Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692939 · ClinicalTrials.gov registry record · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
A Phase 1 study of Crohn's Disease, sponsored by Paul Szabolcs.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT00692939 is a Phase 1 study of Crohn's Disease that is actively recruiting participants, run by Paul Szabolcs. The registered enrollment target is 20 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00692939, a Phase 1 study of Crohn's Disease, is actively recruiting participants, sponsored by Paul Szabolcs.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Alemtuzumab
- DRUG Thiotepa
- BIOLOGICAL autologous CD34-selected peripheral blood stem cells transplant
- DRUG ATG
Study Locations (2)
Pennsylvania
- UPMC Prebyterian- Adult Gastroenterology - Pittsburgh
- Children's Hospital of Pittsburgh of UPMC-Bone Marrow Team - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-06-26 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00692939
The ClinicalTrials.gov registry entry for NCT00692939 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (99% lower). The listed sponsor is Paul Szabolcs, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT00692939 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00692939 about?
NCT00692939 is a clinical study titled "Autologous Stem Cell Transplantation for Crohn's Disease". The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.
What is the current status of trial NCT00692939?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-06-26. Estimated completion is 2027-12.
What conditions does trial NCT00692939 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00692939?
The interventions under investigation include: Melphalan (DRUG), Alemtuzumab (DRUG), Thiotepa (DRUG), autologous CD34-selected peripheral blood stem cells transplant (BIOLOGICAL), ATG (DRUG).
Who is sponsoring clinical trial NCT00692939?
This trial is sponsored by Paul Szabolcs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00692939 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
RECRUITING · Phase 1
-
Beta-Hydroxybutyrate Feasibility Treating IBD
RECRUITING · Phase 1
-
Treatment of Moderate to Severe Refractory Crohn's Disease
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
ACTIVE NOT RECRUITING · Phase 1
-
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
COMPLETED · Phase 1
-
Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.